In stent restenosis and thrombosis assessment after EP224283 injection in a rat model

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 462-468

  Maurel, Blandine ^a,b   Chai, Feng ^a   Maton, Mickael ^a   Blanchemain, Nicolas ^a   Haulon, Stephan ^a,b  

^a CHU de Lille   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Atherosclerosis; EP224283; Factor Xa inhibitor; GPIIbIIIa antagonist; In stent restenosis; Stent thrombosis

Indexed keywords

EP 224283; IDRAPARINUX; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CARDIOVASCULAR STENT; CELL PROLIFERATION; CONTROLLED STUDY; DEVICE REMOVAL; DOWN REGULATION; DRUG EFFICACY; DRUG HALF LIFE; IN VITRO STUDY; IN-STENT RESTENOSIS; MALE; MORPHOMETRICS; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; UPREGULATION;

ATHEROSCLEROSIS; EP224283; FACTOR XA INHIBITOR; GPIIBIIIA ANTAGONIST; IN-STENT RESTENOSIS; STENT THROMBOSIS;

ANGIOPLASTY, BALLOON; ANIMALS; AORTA; BIOTIN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FACTOR XI; GRAFT OCCLUSION, VASCULAR; MALE; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; OLIGOSACCHARIDES; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; RATS, WISTAR; RECURRENCE; STENTS; THROMBOSIS;

EID: 84880608962     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.06.009     Document Type: Article

References (30)

1. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. NEngl J Med 2003, 349:1315-1323.
2. Lejay A., Georg Y., Bajcz C., Thaveau F., Geny B., Kretz J.G., et al. Endovascular treatment of infra-popliteal arteries in patients with critical limb ischemia. Acta Chir Belg 2009, 109:684-693.
3. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al. Apolymer-based, paclitaxel-eluting stent in patients with coronary artery disease. NEngl J Med 2004, 350:221-231.
4. Curcio A., Torella D., Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 2011, 75:1287-1296.
5. Mitra A.K., Agrawal D.K. In stent restenosis: bane of the stent era. JClin Pathol 2006, 59:232-239.
6. Muto A., Fitzgerald T.N., Pimiento J.M., Maloney S.P., Teso D., Paszkowiak J.J., et al. Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons. JVasc Surg 2007, 45(Suppl.A):A15-A24.
7. Topol E.J., Mark D.B., Lincoff A.M., Cohen E., Burton J., Kleiman N., et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1999, 354:2019-2024.
8. Hong Y.J., Jeong M.H., Kim W., Lim S.Y., Lee S.H., Hong S.N., et al. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. Am J Cardiol 2004, 94:1050-1054.
9. Kim W., Jeong M.H., Kim K.H., Sohn I.S., Hong Y.J., Park H.W., et al. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction. JAm Coll Cardiol 2006, 47:933-938.
10. De Scheerder I., Wang K., Wilczek K., Meuleman D., Van Amsterdam R., Vogel G., et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997, 95:1549-1553.
11. Matsumoto Y., Shimokawa H., Morishige K., Eto Y., Takeshita A. Reduction in neointimal formation with a stent coated with multiple layers of releasable heparin in porcine coronary arteries. JCardiovasc Pharmacol 2002, 39:513-522.
12. Mehran R., Aymong E.D., Ashby D.T., Fischell T., Whitworth H., Siegel R., et al. Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an antithrombotic regimen of aspirin alone) study. Circulation 2003, 108:1078-1083.
13. Hechler B., Freund M., Alame G., Leguay C., Gaertner S., Cazenave J.P., et al. The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds. JPharmacol Exp Ther 2011, 338:412-420.
14. Vickers S., Theoharides A.D., Arison B., Balani S.K., Cui D., Duncan C.A., et al. Invitro and invivo studies on the metabolism of tirofiban. Drug Metab Dispos 1999 Nov, 27(11):1360-1366.
15. Lowe H.C., James B., Khachigian L.M. Anovel model of in-stent restenosis: rat aortic stenting. Heart 2005, 91:393-395.
16. Van Beusekom H.M., Whelan D.M., Van de Plas M., Van der Giessen W.J. Apractical and rapid method of histological processing for examination of coronary arteries containing metallic stents. Cardiovasc Pathol 1996, 5(2):69-76.
17. Venkatraman S., Boey F. Release profiles in drug-eluting stents: issues and uncertainties. JControl Release 2007, 120:149-160.
18. Guyton J.R., Rosenberg R.D., Clowes A.W., Karnovsky M.J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. Invivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 1980, 46:625-634.
19. Lablanche J.M., McFadden E.P., Meneveau N., Lusson J.R., Bertrand B., Metzger J.P., et al. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale. Circulation 1997, 96:3396-3402.
20. Kiesz R.S., Buszman P., Martin J.L., Deutsch E., Rozek M.M., Gaszewska E., et al. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: polish-American local Lovenox NIR assessment study (The POLONIA study). Circulation 2001, 103:26-31.
21. Evans D.J., Jackman L.E., Chamberlain J., Crosdale D.J., Judge H.M., Jetha K., et al. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009, 119:116-122.
22. Pcak P. GPIIbIIIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost 2012, 107:808-814.
23. Hedin U., Roy J., Tran P.K. Control of smooth muscle cell proliferation in vascular disease. Curr Opin Lipidol 2004, 15:559-565.
24. Marra D.E., Simoncini T., Liao J.K. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation 2000, 102:2124-2130.
25. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002, 8:1249-1256.
26. Miura S., Matsuo Y., Kawamura A., Saku K. JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/p21(waf1) pathways. Atherosclerosis 2005, 182:267-275.
27. Haude M., Konorza T.F., Kalnins U., Erglis A., Saunamaki K., Glogar H.D., et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003, 107:1265-1270.
28. Moliterno D.J., Committee T.S. Arandomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv 2011, 77:1001-1009. Investigators.
29. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 2004, 109:701-705.
30. Bangalore S., Vlachos H.A., Selzer F., Wilensky R.L., Kip K.E., Williams D.O., et al. Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the national heart, lung, and blood institute dynamic registry. Catheter Cardiovasc Interv 2011, 77:22-28.